Foster Group, Inc. Bristol Myers Squibb CO Transaction History

Foster Group, Inc.

$2.01 Billion
Q1 2024

A detailed history of Foster Group, Inc. transactions in Bristol Myers Squibb CO stock. As of the latest transaction made, Foster Group, Inc. holds 6,673 shares of BMY stock, worth $272,658. This represents 0.02% of its overall portfolio holdings.

Number of Shares

6,673

Previous 7,263 8.12%

Holding current value

$272,658

Previous $372,000 2.96%

% of portfolio

0.02%

Previous 0.02%

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 Apr 09, 2024	SELL	$47.98 - $54.4 $28,308 - $32,096	-590 Reduced 8.12%	6,673 $361,000
Q3 2023 Oct 27, 2023	BUY	$57.89 - $64.73 $34,734 - $38,838	600 Added 9.0%	7,263 $421,000
Q2 2023 Jul 10, 2023	BUY	$63.71 - $70.74 $9,492 - $10,540	149 Added 2.29%	6,663 $426,000
Q1 2023 Apr 06, 2023	SELL	$65.71 - $74.53 $28,058 - $31,824	-427 Reduced 6.15%	6,514 $451,000
Q4 2022 Jan 23, 2023	BUY	$68.48 - $81.09 $10,135 - $12,001	148 Added 2.18%	6,941 $0

Q3 2022 Oct 13, 2022	BUY	$0.13 - $76.84 $44 - $26,202	341 Added 5.29%	6,793 $483,000
Q2 2022 Jul 25, 2022	BUY	$72.62 - $79.98 $95,858 - $105,573	1,320 Added 25.72%	6,452 $497,000
Q1 2022 Apr 22, 2022	BUY	$61.48 - $73.72 $676 - $810	11 Added 0.21%	5,132 $375,000
Q4 2021 Feb 02, 2022	SELL	$53.63 - $62.52 $3,271 - $3,813	-61 Reduced 1.18%	5,121 $319,000
Q2 2021 Aug 09, 2021	BUY	$61.91 - $67.42 $4,828 - $5,258	78 Added 1.53%	5,182 $346,000
Q4 2020 Jan 21, 2021	BUY	$57.74 - $65.43 $294,704 - $333,954	5,104 New	5,104 $312,000

Others Institutions Holding BMY

# of Institutions

2,557

Shares Held

1.49B

Call Options Held

25.9M

Put Options Held

20M

View Full List

About BRISTOL MYERS SQUIBB CO

Ticker BMY
Exchange NYSE
Sector Healthcare
Industry Drug Manufacturers—General
Shares Outstandng 2,126,160,000
Market Cap $86.9B
Description
Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, and markets biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, neuroscience, and covid-19 diseases. The company's products include Revlimid, an oral immunomodulatory drug for the treatment of multiple my...

More about BMY

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Foster Group, Inc., based on Form 13F filings with the SEC.

News

Stay updated on Foster Group, Inc. with notifications on news.

Account